Heartland NCORP sites implement drive-through laboratory service

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Two component institutions of Heartland Cancer Research NCORP have created drive-through laboratory services for outpatients during the COVID-19 crisis.

The service does not test patients for coronavirus infection, but provides a mechanism for patients with cancer and blood diseases to have laboratory studies for treatment or clinical trial requirements in the safest possible manner. The drive-up laboratory sites meet the requirements of the state and local governments’ shelter-in-place orders.

At both Springfield Clinic (Springfield, IL; Preet P. Singh, Sub-PI for Disparities and Cancer Care Delivery Research) and Missouri Baptist Medical Center (St. Louis, MO; Bryan A Faller, principal investigator), upon arrival, the patient drives into a designated parking area, calls the registration area and registers for the visit by telephone.

A phlebotomist is sent to the patient’s vehicle and performs the blood draw with the patient’s arm extended through the window. After the drive-through visit, the patient obtains results and further instructions by telephone or via the patient portal.

Springfield Clinic has developed an educational video for patients, describing the service. The service has been popular at both NCORP sites and may be a model for patient-centered service after the pandemic subsides.

Table of Contents

YOU MAY BE INTERESTED IN

The University of California, San Francisco and global oncology communities mourn the death of Felix Y. Feng, MD, a radiation oncologist and a leading figure in genitourinary cancer research. A professor of radiation oncology, urology and medicine, and vice chair of translational research at the UCSF Helen Diller Family Comprehensive Cancer Center, Feng died from cancer on Dec.10, 2024. He was 48.
The late Felix Feng, MD (center) with researchers Jonathan Chou, MD, PhD (left) and Lisa Chesner, PhD (right), in 2019.Photo by Noah BergerFelix Y. Feng, a genitourinary cancer research leader, died on Dec. 10, 2024. He was 48.This article is republished with permission by NRG Oncology.Dr. Feng was the former NRG Oncology Genitourinary Cancer Committee chair and an RTOG Foundation member. After years of dedicated and enthusiastic commitment to the NRG and previously the RTOG Genitourinary Cancer Committee, chairing or co-chairing 13 research protocols for NRG and RTOG, Dr. Feng was appointed committee chair in March 2018, following in the footsteps of Dr. Howard Sandler, his mentor. Dr. Feng was also a member of the RTOG Foundation Board of Directors.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login